<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"><channel><title><![CDATA[AdvanCell 보도자료 - 뉴스와이어]]></title><link>https://www.newswire.co.kr/?md=A10&amp;act=article&amp;no=41321></link><description><![CDATA[AdvanCell 보도자료 - 뉴스와이어 RSS 서비스]]></description><lastBuildDate>Thu, 14 May 2026 05:25:45 +0900</lastBuildDate><copyright>Copyright (c) 2004~2026 Korea Newswire All rights reserved</copyright><image><url><![CDATA[https://file.newswire.co.kr/data/upfile/company_img/2022/08/12_1028147215_20220825095340_1872345659.jpg]]></url></image><language>ko-KR</language><item><title><![CDATA[AdvanCell Closes A$18M Series B Funding Led by Morningside]]></title><link>https://www.newswire.co.kr/newsRead.php?no=950055</link><description><![CDATA[Sydney--(Business Wire/Korea Newswire)--AdvanCell, an Australian radiopharmaceutical company with a platform technology for a revolutionary cancer treatment called Targeted Alpha Therapy, announced today the closing of an A$18 million Series B financing round led by Morningside.  Andrew Adamovich, CEO and Founder of AdvanCell noted, “We are very pleased with our progress to date and d...]]></description><pubDate>Thu, 25 Aug 2022 10:30:00 +0900</pubDate></item><item><title><![CDATA[어드밴셀, 모닝사이드 주도 1800만 호주달러 규모 시리즈 B 펀딩 마감]]></title><link>https://www.newswire.co.kr/newsRead.php?no=950056</link><description><![CDATA[Sydney--(Business Wire/뉴스와이어)--표적 알파 치료(Targeted Alpha Therapy)라는 획기적 암 치료를 위한 플랫폼 기술을 보유한 호주 방사성 제약 회사 어드밴셀(AdvanCell)은 모닝사이드(Morningside)가 주도하는 1800만 호주달러 규모의 시리즈 B 자금 조달 라운드를 마감했다고 8월 25일 밝혔다.  앤드루 아다모비치(Andrew Adamovich) 어드밴셀 최고 경영자 겸 설립자는 “어드밴셀은 현재까지 진행 상황에 ...]]></description><pubDate>Thu, 25 Aug 2022 10:30:00 +0900</pubDate></item></channel></rss>